Document Detail

Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia.
MedLine Citation:
PMID:  10634827     Owner:  NLM     Status:  MEDLINE    
Patients with combined hyperlipemia have lipid abnormalities associated with an increased tendency to develop atherosclerosis and thrombosis. This tendency may be accelerated during postprandial hyperlipemia. In the present double-blind parallel study, 41 patients with combined hyperlipemia and serum triacylglycerols between 2.0 and 15.0 mmol/L and serum total cholesterol >5.3 mmol/L at the end of a 3-month dietary run-in period were treated with simvastatin at 20 mg/d for at least 10 weeks; patients were then randomized into 2 groups receiving simvastatin+omega-3 fatty acids at 3.36 g/d or placebo (corn oil) for an additional 5 weeks. Hemostatic variables that have been associated with increased thrombotic tendency were evaluated with subjects in the fasting state and during postprandial hyperlipemia before and after combined treatment. Supplementation of omega-3 fatty acid reduced tissue factor pathway inhibitor antigen (P<0.05) in the fasting state, reduced the degree of postprandial hyperlipemia (P<0.005), and reduced activated factor VII concentration appearing during postprandial hyperlipemia. In conclusion, omega-3 fatty acids given in addition to simvastatin to patients with combined hyperlipemia reduced the free tissue factor pathway inhibitor fraction in the fasting state and inhibited the activation of factor VII occurring during postprandial lipemia, thus representing a potential beneficial effect on the hemostatic risk profile in this patient group.
A Nordoy; K H Bonaa; P M Sandset; J B Hansen; H Nilsen
Related Documents :
9208387 - Dietary effect of a symmetrical triacylglycerol, 1,3-biseicosapentaenoyl-2-gamma-linole...
19859067 - Omega-3 fatty acids: cardiovascular benefits, sources and sustainability.
15023647 - Feeding regimes affect fatty acid composition in australian beef cattle.
9164707 - Omega-3 fatty acids in the prevention-management of cardiovascular disease.
23999517 - Comparison of the efficiency of different antibiotic irrigation solutions in decontamin...
18421757 - Towards new antimalarial drugs: synthesis of non-hydrolyzable phosphate mimics as feed ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  20     ISSN:  1079-5642     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2000 Jan 
Date Detail:
Created Date:  2000-01-28     Completed Date:  2000-01-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  259-65     Citation Subset:  IM    
Department of Medicine, University of Tromso, Tromso, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / administration & dosage*
Blood Glucose / metabolism
Dietary Fats / administration & dosage
Double-Blind Method
Eating / physiology
Factor VIIa / metabolism
Fatty Acids, Omega-3 / administration & dosage*
Hemostasis / drug effects
Hyperlipidemias / blood,  complications,  drug therapy*
Lipoproteins / blood
Middle Aged
Risk Factors
Simvastatin / administration & dosage*
Thrombosis / blood,  etiology,  prevention & control
Reg. No./Substance:
0/Antilipemic Agents; 0/Blood Glucose; 0/Dietary Fats; 0/Fatty Acids, Omega-3; 0/Lipoproteins; 0/lipoprotein-associated coagulation inhibitor; 79902-63-9/Simvastatin; EC VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and ...
Next Document:  Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydro...